SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech Valuation
An SI Board Since February 1999
Posts SubjectMarks Bans Symbol
52157 680 3 CRSP
Emcee:  Biomaven Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
50653Thanks for the help here. My trading platform shows no FGEN options with an exptuck-1/11/2019
50652Thanks Bulba!Robohogs-1/10/2019
50651The 2018 Shkreli Awards, a top ten list of the worst examples of profiteering anBulbaMan-1/9/2019
50650That is interesting - of course we don't know if we really want EPA in the bBiomaven-1/9/2019
50649Dietary lysophosphatidylcholine-EPA enriches both EPA and DHA in the brain: Potenigel bates21/9/2019
50648RE:FDA (JPM) Dr. Scott Gottlieb is the most matching FDA head, bay far,...and KMiljenko Zuanic11/8/2019
50647geekwire.com Former Juno Therapeutics executives Hans Bishop and Steve Harr havkeokalani'nui11/8/2019
50646Nektar jumps nearly 10% after laying out anticipated milestones for 2019 theflyJulius Wong-1/8/2019
50645both serious and entertaining. thanks for the morning chuckle:-)teevee-1/8/2019
50644Thanks very much, I'll take a look. Very happy with a modest buy at the endscaram(o)uche-1/8/2019
50643The dependent variable classification is categorical rather than continuous, so glass 0.5 full11/8/2019
50642Dextromethorphan appears to do some good stuff in general if you are able to modoldirtybastard11/8/2019
50641Biotech’s breaking out, and here’s why some market experts think an even bigger biocqr-1/8/2019
50640I hadn't seen that press release until you pointed it out. $8 per share. Notbmaz00121/8/2019
50639Did you see what they did? ATM out with Leerink. Bewildering. Forget the secoscaram(o)uche-1/7/2019
50638Here's a year old article on NDD-CKD in U.S. renalandurologynews.comwinbiggs-1/7/2019
50637[graphic]bmaz001-1/7/2019
50636NCT03471767bmaz001-1/7/2019
50635It looks like AXSM also has phase 2 top line data for smoking cessation due thisbmaz001-1/7/2019
50634>> Probably hear of an offering within the next 10 minutes, give or take atuck11/7/2019
50633Anybody looked at AXSM? NMDA receptor antagonist, results today in refractory dscaram(o)uche-1/7/2019
50632Maybe not to halt CKD progression, but make it more manageable, less costly, betMiljenko Zuanic-1/7/2019
50631Thanks Miljenko. Do any of Roxa's reimbursement prospects lie in the promisatticus4paws-1/7/2019
50630First ~4 months mortality rate after dialysis treatment started was due, IMO, inMiljenko Zuanic-1/7/2019
50629After watching that presentation, I found it interesting that the presenter sinatticus4paws-1/7/2019
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News